P383 Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada | Zendy

AI Assistant Blog Pricing

P383 Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.